Kriya Therapeutics Stock
HealthTechLooking to sell Kriya Therapeutics stock or options?
Kriya Therapeutics, a gene therapy company, is committed to the design and development of gene therapies for diseases with fundamental biological underpinnings. The company employs a vector design platform that enhances its ability to perform de novo construct design, targeted sequence modification and data analysis. This enables physicians to reduce immunogenicity and enhance tissue specificity.
Sahsen Ventures, Dexcel Pharma, Transhuman Capital, Hongkou Capital, Asia Alpha, Lightswitch (PTY), Breakthrough T1D, Patient Square Capital, Bluebird Ventures, Alumni Ventures, Anjost Investment, Paul Manning, CAM Capital, T1D Fund, Foresite Capital, Amplo, Resolved Ventures, Woodline Partners, QVT Family Office, Narya.